NVCR Insider Trading
NovoCure Ltd | Surgical & Medical Instruments & Apparatus
Comprehensive Trading Performance Summary
The investment history of corporate insiders at NovoCure Ltd provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Surgical & Medical Instruments & Apparatus sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-08 14:10 | 2025-09-05 | Cordova Ashley | Officer - Chief Executive Officer | BUY | $12.22 | 81,550 | $996,859 | 437,569 | +22.9% |
| 2025-07-30 23:33 | 2025-07-29 | Brackmann Christoph | Officer - Chief Financial Officer | BUY | $11.59 | 20,000 | $231,800 | 141,150 | +16.5% |
| 2025-06-04 23:26 | 2025-06-03 | Stafford Kristin | Director | SELL | $17.28 | 999 | $17,259 | 3,054 | -24.6% |
| 2025-06-04 23:24 | 2025-06-03 | LEUNG GABRIEL | Director | SELL | $17.31 | 999 | $17,297 | 81,229 | -1.2% |
| 2025-06-04 23:23 | 2025-06-03 | Madden Martin J. | Director | SELL | $17.19 | 999 | $17,176 | 18,674 | -5.1% |
| 2025-06-04 23:22 | 2025-06-03 | Scannell Timothy J | Director | SELL | $17.32 | 999 | $17,299 | 6,018 | -14.2% |
| 2025-06-04 23:17 | 2025-06-03 | HILLEMAN JERYL L | Director | SELL | $17.26 | 999 | $17,247 | 5,591 | -15.2% |
| 2025-06-04 23:16 | 2025-06-03 | Ocean Allyson J | Director | SELL | $17.29 | 999 | $17,269 | 3,054 | -24.6% |
| 2025-06-04 23:14 | 2025-06-03 | VERNON W ANTHONY | Director | SELL | $17.35 | 999 | $17,329 | 167,887 | -0.6% |
| 2025-06-04 23:11 | 2025-06-03 | Hung David | Director | SELL | $17.30 | 999 | $17,280 | 12,195 | -7.6% |
| 2025-06-04 23:09 | 2025-06-02 | Leonard Frank X | Officer - EVP, Pres., Novocure Oncology | SELL | $17.50 | 30,196 | $528,412 | 168,452 | -15.2% |
| 2025-05-05 23:17 | 2025-05-03 | Paravasthu Mukund | Officer - Chief Operating Officer | SELL | $17.91 | 592 | $10,604 | 83,556 | -0.7% |
| 2025-03-05 00:19 | 2025-03-03 | Weinberg Uri | Officer - Chief Innovation Officer | SELL | $18.92 | 268 | $5,071 | 166,243 | -0.2% |
| 2025-03-05 00:19 | 2025-03-03 | Leonard Frank X | Officer - EVP, Pres., Novocure Oncology | SELL | $18.54 | 2,527 | $46,841 | 143,673 | -1.7% |
| 2025-03-05 00:19 | 2025-03-03 | Cordova Ashley | Officer - Chief Executive Officer | SELL | $18.54 | 2,053 | $38,055 | 204,005 | -1.0% |
| 2025-03-05 00:16 | 2025-03-03 | Paravasthu Mukund | Officer - Chief Operating Officer | SELL | $18.54 | 250 | $4,634 | 29,173 | -0.8% |
| 2025-03-04 05:27 | 2025-02-28 | Weinberg Uri | Officer - Chief Innovation Officer | SELL | $18.75 | 4,637 | $86,949 | 166,511 | -2.7% |
| 2025-03-04 05:26 | 2025-02-27 | Cordova Ashley | Officer - Chief Executive Officer | SELL | $19.72 | 13,494 | $266,126 | 206,058 | -6.1% |
| 2025-03-04 05:26 | 2025-02-27 | Leonard Frank X | Officer - EVP, Pres., Novocure Oncology | SELL | $19.70 | 15,036 | $296,257 | 146,200 | -9.3% |
| 2025-03-04 05:26 | 2025-02-27 | Puri Michal Nath | Officer - Chief Human Resources Officer | SELL | $20.02 | 1,387 | $27,773 | 108,706 | -1.3% |
| 2025-03-04 05:26 | 2025-02-27 | Leupin Nicolas | Officer - Chief Medical Officer | SELL | $20.02 | 991 | $19,844 | 50,133 | -1.9% |
| 2025-03-04 05:26 | 2025-02-27 | Paravasthu Mukund | Officer - Chief Operating Officer | SELL | $19.71 | 2,014 | $39,687 | 29,423 | -6.4% |
| 2025-01-16 00:23 | 2025-01-11 | Paravasthu Mukund | Officer - Chief Operating Officer | SELL | $26.81 | 2,160 | $57,906 | 31,437 | -6.4% |
| 2024-11-07 00:27 | 2024-11-02 | Paravasthu Mukund | Officer - Chief Operating Officer | SELL | $16.69 | 44 | $734 | 3,459 | -1.3% |
| 2024-11-05 00:34 | 2024-10-31 | Puri Michal Nath | Officer - Chief Human Resources Officer | SELL | $15.79 | 810 | $12,792 | 110,093 | -0.7% |
| 2024-11-05 00:34 | 2024-11-01 | Leonard Frank X | Officer - EVP, Pres., Novocure Oncology | SELL | $15.94 | 598 | $9,531 | 161,236 | -0.4% |
| 2024-11-05 00:32 | 2024-11-01 | Paravasthu Mukund | Officer - Chief Operating Officer | SELL | $15.88 | 160 | $2,540 | 3,503 | -4.4% |
| 2024-08-05 23:25 | 2024-08-02 | Cordova Ashley | Officer - Chief Financial Officer | SELL | $20.14 | 688 | $13,857 | 219,179 | -0.3% |
| 2024-06-07 00:43 | 2024-06-04 | VERNON W ANTHONY | Director | SELL | $23.89 | 964 | $23,033 | 164,833 | -0.6% |
| 2024-06-07 00:42 | 2024-06-04 | Scannell Timothy J | Director | SELL | $23.89 | 964 | $23,027 | 2,964 | -24.5% |
| 2024-06-07 00:42 | 2024-06-04 | LEUNG GABRIEL | Director | SELL | $23.89 | 964 | $23,025 | 78,175 | -1.2% |
| 2024-03-06 00:09 | 2024-03-01 | GROENHUYSEN WILHELMUS CM | Officer - Chief Operating Officer | SELL | $16.02 | 3,324 | $53,253 | 251,235 | -1.3% |
| 2024-03-06 00:08 | 2024-03-01 | Leonard Frank X | Officer - EVP, Pres., Novocure Oncology | SELL | $16.02 | 2,519 | $40,358 | 160,098 | -1.5% |
| 2024-03-01 00:38 | 2024-02-28 | Leonard Frank X | Officer - EVP, Pres., Novocure Oncology | SELL | $16.14 | 2,078 | $33,545 | 162,617 | -1.3% |
| 2024-03-01 00:28 | 2024-02-28 | GROENHUYSEN WILHELMUS CM | Officer - Chief Operating Officer | SELL | $16.14 | 2,303 | $37,177 | 254,559 | -0.9% |
| 2023-11-09 00:22 | 2023-11-07 | Shah Pritesh | Officer - Chief Growth Officer | SELL | $12.65 | 382 | $4,832 | 124,511 | -0.3% |
| 2023-09-05 23:24 | 2023-09-01 | Cordova Ashley | Officer - Chief Financial Officer | SELL | $21.82 | 883 | $19,265 | 99,650 | -0.9% |
| 2023-09-05 23:24 | 2023-09-01 | GROENHUYSEN WILHELMUS CM | Officer - Chief Operating Officer | SELL | $21.82 | 294 | $6,414 | 209,825 | -0.1% |
| 2023-09-05 23:23 | 2023-09-01 | Shah Pritesh | Officer - Chief Growth Officer | SELL | $21.82 | 273 | $5,956 | 124,893 | -0.2% |
| 2023-08-04 23:02 | 2023-08-02 | Cordova Ashley | Officer - Chief Financial Officer | SELL | $30.25 | 1,144 | $34,607 | 100,533 | -1.1% |
| 2023-03-08 00:52 | 2023-03-03 | Leonard Frank X | Officer - President, CNS Cancers US | SELL | $75.55 | 13,609 | $1,028,164 | 54,284 | -20.0% |
| 2023-03-08 00:52 | 2023-03-03 | Shah Pritesh | Officer - Chief Growth Officer | SELL | $76.16 | 21,421 | $1,631,411 | 124,799 | -14.6% |
| 2023-03-08 00:51 | 2023-03-03 | GROENHUYSEN WILHELMUS CM | Officer - Chief Operating Officer | SELL | $76.16 | 25,635 | $1,952,346 | 209,753 | -10.9% |
| 2023-03-08 00:51 | 2023-03-03 | Cordova Ashley | Officer - Chief Financial Officer | SELL | $76.16 | 5,505 | $419,257 | 101,310 | -5.2% |
| 2023-03-08 00:50 | 2023-03-03 | Burke William Patrick | Officer - Chief Human Resources Officer | SELL | $76.16 | 593 | $45,163 | 66,090 | -0.9% |
| 2023-03-07 00:42 | 2023-03-02 | Burke William Patrick | Officer - Chief Human Resources Officer | SELL | $75.28 | 281 | $21,153 | 66,683 | -0.4% |
| 2023-03-07 00:41 | 2023-03-02 | Shah Pritesh | Officer - Chief Growth Officer | SELL | $75.28 | 937 | $70,535 | 99,038 | -0.9% |
| 2023-03-07 00:40 | 2023-03-02 | GROENHUYSEN WILHELMUS CM | Officer - Chief Operating Officer | SELL | $75.28 | 1,213 | $91,312 | 183,402 | -0.7% |
| 2023-03-07 00:40 | 2023-03-02 | Cordova Ashley | Officer - Chief Financial Officer | SELL | $75.28 | 1,055 | $79,418 | 95,007 | -1.1% |
| 2023-03-07 00:37 | 2023-03-02 | Leonard Frank X | Officer - President, CNS Cancers US | SELL | $76.95 | 2,903 | $223,393 | 67,893 | -4.1% |
How to Interpret $NVCR Trades
Not every insider transaction in NovoCure Ltd is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $NVCR shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for NVCR
Insider activity data for NovoCure Ltd is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $NVCR, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.